Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOWARD ILIVICKY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1093711152
CMS profile
321069
Location
SAINT CHARLES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,273.50

195 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,468.62 189
Travel and Lodging $780.86 4
Education $24.02 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOWARD ILIVICKY

NPI 1093711152 · CMS profile ID 321069

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

SAINT CHARLES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093711152?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOWARD ILIVICKY, NPI 1093711152, CMS profile ID 321069. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093711152?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HOWARD ILIVICKY, NPI 1093711152, CMS profile ID 321069. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093711152?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HOWARD ILIVICKY, NPI 1093711152, CMS profile ID 321069, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1093711152?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

195 matching records · $4,273.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 195 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 195.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $11.8706/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133906905 CMS
ABBVIE INC. $5.7506/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103965113 CMS
Noven Therapeutics, LLC $19.2706/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084821145 CMS
Alkermes, Inc. $1.1506/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120521053 CMS
Alkermes, Inc. $10.3806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120521055 CMS
Teva Pharmaceuticals USA, Inc. $18.2906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151483301 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137583620 CMS
Vanda Pharmaceuticals Inc. $29.8406/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133906903 CMS
Neurocrine Biosciences, Inc. $2.9706/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150889982 CMS
Neurocrine Biosciences, Inc. $28.5606/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150829384 CMS
IRONSHORE PHARMACEUTICALS INC. $10.3005/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146245719 CMS
Noven Therapeutics, LLC $15.3205/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084821143 CMS
Bausch Health US, LLC $14.6905/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148019976 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12.1505/28/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143246267 CMS
Teva Pharmaceuticals USA, Inc. $15.3105/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151483281 CMS
Alkermes, Inc. $10.6605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120521051 CMS
Otsuka America Pharmaceutical, Inc. $15.5005/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118912049 CMS
Otsuka America Pharmaceutical, Inc. $1.5905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118912051 CMS
Axsome Therapeutics, Inc. $16.2005/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148285213 CMS
Lundbeck LLC $11.0805/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145927354 CMS
IRONSHORE PHARMACEUTICALS INC. $16.8705/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146264641 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2.8405/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143246256 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $0.1905/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143246260 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $21.0705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143246263 CMS
Teva Pharmaceuticals USA, Inc. $19.7005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151483279 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.2005/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137583616 CMS
Vanda Pharmaceuticals Inc. $29.8405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133906901 CMS
ABBVIE INC. $29.5605/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103965111 CMS
Neos Therapeutics, LP $16.0505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082668963 CMS
Neurocrine Biosciences, Inc. $16.2005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150871582 CMS
ABBVIE INC. $28.8404/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103965109 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5.8304/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143246252 CMS
Sage Therapeutics, Inc. $17.1104/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120404074 CMS
Noven Therapeutics, LLC $14.6304/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084821141 CMS
Alkermes, Inc. $19.9804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120521049 CMS
Teva Pharmaceuticals USA, Inc. $20.2804/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151483261 CMS
Tris Pharma Inc $13.4504/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147217280 CMS
Supernus Pharmaceuticals, Inc. $24.2204/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147777362 CMS
LivaNova USA, Inc. $14.5004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152792925 CMS
Otsuka America Pharmaceutical, Inc. $20.0104/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118912047 CMS
ABBVIE INC. $12.7804/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103965107 CMS
Axsome Therapeutics, Inc. $15.5004/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148285211 CMS
Teva Pharmaceuticals USA, Inc. $23.3104/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151483259 CMS
Lundbeck LLC $18.7104/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145927352 CMS
Supernus Pharmaceuticals, Inc. $24.9804/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147777364 CMS
Noven Therapeutics, LLC $13.8703/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084821139 CMS
Neurocrine Biosciences, Inc. $22.5403/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150848496 CMS
Bausch Health US, LLC $15.5103/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148019974 CMS
Otsuka America Pharmaceutical, Inc. $16.5103/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118912045 CMS
Tris Pharma Inc $13.7303/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147217282 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,631.43 117
PY2020 $1,578.50 94
PY2021 $2,038.53 119
PY2022 $3,013.71 131
PY2023 $9,803.20 219
PY2024 $4,273.50 195
PY2025 $1,661.35 93

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $125,573.24 47
PY2024 Principal investigator $273,393.62 28
PY2023 Principal investigator $342,693.19 34
PY2022 Principal investigator $172,868.74 12
PY2021 Principal investigator $171,195.19 52
PY2020 Principal investigator $575,200.96 75
PY2019 Recipient $1,500.05 8
PY2019 Principal investigator $421,830.54 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 06/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680852
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680854
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680856
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680858
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680860
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 05/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680842
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680844
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680846
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680848
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680850
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,920.00 04/28/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220799547
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 04/23/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680862
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 04/23/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680864
Principal investigator 1 Janssen Research & Development, LLC $1,153.00 04/23/2025 Non-covered Recipient Entity
Psychc Care and Rsrch Ctr Inc.
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175236369
Principal investigator 1 Janssen Research & Development, LLC $2,365.00 04/02/2025 Non-covered Recipient Entity
Psychc Care and Rsrch Ctr Inc.
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175236349
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680832
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680834
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680836
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680838
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 04/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680840
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,558.00 03/28/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220799545
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680808
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680810
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680812
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680814
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 03/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680816
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69,406.00 02/27/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220799543
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 02/25/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680822
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 02/25/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680824
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680826
Principal investigator 1 Boehringer Ingelheim International GmbH $14.44 02/25/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680828
Principal investigator 1 Janssen Research & Development, LLC $3,154.00 02/24/2025 Non-covered Recipient Entity
Psychc Care
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175236377
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $1,725.60 02/19/2025 Non-covered Recipient Entity
PSYCHIATRIC CARE AND RESEARCH CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335545
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680798
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680800
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680802
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680804
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680806
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 01/27/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680818
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 01/27/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680820
Principal investigator 1 Janssen Research & Development, LLC $5,644.00 01/24/2025 Non-covered Recipient Entity
Psychc Care
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175236360
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,400.00 01/07/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220799541
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680790
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680792
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680794
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680796
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Psychiatric Care And Research Center Inc
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220680830